Home FDA Approves Mercks NOXAFIL (posaconazole) Delayed-Release Tablets
 

Keywords :   


FDA Approves Mercks NOXAFIL (posaconazole) Delayed-Release Tablets

2013-11-26 15:00:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL (posaconazole) 100 mg delayed-release tablets. NOXAFIL delayed-release tablets are a new formulation with a loading dose of 300 mg (three 100 mg delayed-release tablets) twice daily on the first day, followed by a once-daily maintenance dose of 300 mg (three 100 mg delayed-release tablets) starting on the second day of therapy. Language: English Contact: MerckMedia Contacts:Pam Eisele, 908-423-5042Robert Consalvo, 908-423-6595orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: tablets fda approves fda approves

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
27.11 PSA10 () SCR
27.111108
27.11
27.11
27.11SAKEROCK/ 0
27.11Influence THEROW
27.11 A
27.11FIRSTSPEAR
More »